Titration

Theralink® Technologies Announces Partnership with Perthera to Facilitate and Accelerate Access to its Unique Phosphoprotein and Drug Target Activation Testing in the U.S.

Retrieved on: 
Monday, November 16, 2020

The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients.

Key Points: 
  • The alliance will facilitate and accelerate access to Theralink's 32 phosphoprotein panel, the Theralink assay, across the U.S. for breast cancer patients.
  • This unique assay is the world's only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once.
  • Through this partnership, Perthera will develop and manage Theralink's observational registry trial, TRACE (Theralink Registry to Assess Comprehensive Effectiveness).
  • We look forward to advancing our integrated partnership and driving Theralink's innovative testing across the nation," said Gary Gregory, CEO of Perthera.

Applied DNA Secures Blanket Purchase Order for 10,000 Linea™ COVID-19 Tests

Retrieved on: 
Thursday, November 12, 2020

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has secured a blanket purchase order from an existing customer for its Linea COVID-19 Assay Kit (the Assay Kit) and consumables to conduct 10,000 tests.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has secured a blanket purchase order from an existing customer for its Linea COVID-19 Assay Kit (the Assay Kit) and consumables to conduct 10,000 tests.
  • The Company has already shipped a portion of the purchase order in the current fiscal quarter ending December 31, 2020.
  • The balance of the purchase order is expected to be delivered in the current quarter.
  • The Company anticipates recurring purchase orders for Assay Kits and consumables from the customer.

Global Clinical Chemistry Analyzers and Reagents Market Insights to 2024 - Forecasts for over 100 Tests, Technology and Instrumentation Reviews - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 10, 2020

The report is available by section, and can be customized to specific information needs and budget.

Key Points: 
  • The report is available by section, and can be customized to specific information needs and budget.
  • The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in both centralized (hospitals, commercial laboratories), and POC/decentralized locations.
  • Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.
  • Test volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays.

Pyrogen Testing Market worth $1,689 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 10, 2020

Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market.

Key Points: 
  • Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market.
  • The assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market, by product & service segment, in 2019
    Based on product & service, the market is segmented into assays, kits, and reagents; instruments; and services.
  • The assays, kits, & reagents segment accounted for the largest share of the market in 2019.
  • The pyrogen testing market is segmented into LAL tests, in vitro tests, and rabbit tests based on test type.

Pyrogen Testing Market worth $1,689 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, November 10, 2020

Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market.

Key Points: 
  • Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market.
  • The assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market, by product & service segment, in 2019
    Based on product & service, the market is segmented into assays, kits, and reagents; instruments; and services.
  • The assays, kits, & reagents segment accounted for the largest share of the market in 2019.
  • The pyrogen testing market is segmented into LAL tests, in vitro tests, and rabbit tests based on test type.

Stony Brook University Hospital Launches COVID-19 Surveillance Testing Program Powered by Applied DNA’s Assay Kit and Services

Retrieved on: 
Tuesday, November 10, 2020

Applied DNA Sciences, Inc., (NASDAQ: APDN) (Applied DNA or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea COVID-19 Assay Kit (the Assay Kit) has been selected by Stony Brook University Hospital (SBUH) for use in SBUHs newly launched COVID-19 surveillance testing program (the Program).

Key Points: 
  • Applied DNA Sciences, Inc., (NASDAQ: APDN) (Applied DNA or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea COVID-19 Assay Kit (the Assay Kit) has been selected by Stony Brook University Hospital (SBUH) for use in SBUHs newly launched COVID-19 surveillance testing program (the Program).
  • The Program is modeled after the Companys proprietary safeCircle platform, a pooled surveillance testing program developed and used in-house by the Companys Applied DNA Clinical Laboratories (ADCL) subsidiary.
  • safeCircle utilizes the Companys Assay Kit in conjunction with an automated, high-throughput testing workflow and equipment, software, and services to return pooled surveillance test results typically within 24 hours.
  • Offering our high sensitivity Assay Kit for use in a surveillance testing modality creates additional sales opportunities, stated Dr. James A. Hayward, president and CEO, Applied DNA.

Global Neuroscience Antibodies and Assays Market Analysis Report 2020-2024 - Industry Growth Rate Projection With CAGR of Over 8% and Current Trends, Share, Size, Top Players With Its Type and Applications | Technavio

Retrieved on: 
Friday, November 6, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201105005767/en/
    Technavio has announced its latest market research report titled Global Neuroscience Antibodies and Assays Market 2020-2024 (Graphic: Business Wire).
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The report on the neuroscience antibodies and assays market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The neuroscience antibodies and assays market analysis includes product segment and geography landscape.
  • This study identifies the advances in neuroscience instruments as one of the prime reasons driving the neuroscience antibodies and assays market growth during the next few years.

Nexcelom to Hold Virtual "Modern Cell-Based Assays" Symposium, November 10, 2020

Retrieved on: 
Thursday, November 5, 2020

Whether you are working with cell culture, 3D assays, virology assays, or advanced cell models, there will be something for you at this engaging event.

Key Points: 
  • Whether you are working with cell culture, 3D assays, virology assays, or advanced cell models, there will be something for you at this engaging event.
  • Streamline your workflow with diversified technology that can be utilized across a variety of research areas.
  • With multiple patents pending, Nexcelom is a clear leader and innovator in the field of image-based cytometry for cell analysis.
  • LabRoots is the leading scientific social networking website, and primary source for scientific trending news and premier educational virtual events and webinars and more.

Micronoma Expands Executive Team and Operations

Retrieved on: 
Thursday, November 5, 2020

Eddie joins the Micronoma executive team with the responsibility of leading the scientific development of Micronoma's diagnostic assays, growing the scientific team, and most immediately, leading a utility trial for Micronoma's first offering, a diagnostic for the early detection of lung cancer.

Key Points: 
  • Eddie joins the Micronoma executive team with the responsibility of leading the scientific development of Micronoma's diagnostic assays, growing the scientific team, and most immediately, leading a utility trial for Micronoma's first offering, a diagnostic for the early detection of lung cancer.
  • For Micronoma, Darryl will establish the CLIA labs, as well as assist with all processes and workflow implementation to ensure that Micronoma is ready to process patient samples as soon as possible.
  • Micronoma also announced their new headquarters in San Diego and is aiming to be CLIA certified by late 2021.
  • "I am very happy with our growing team, balanced with industry pedigree and new brilliance," said Sandrine Miller-Montgomery, CEO of Micronoma.

ENZO LAUNCHES PORTABLE MICROPLATE READER FOR USE WITH ITS ELISA AND ASSAY KITS TO SIMPLIFY LABORATORY WORKFLOW

Retrieved on: 
Thursday, November 5, 2020

Enzo is the provider of over 17,000 ELISA (enzyme-linked immunosorbent assay) and assay kits, including hundreds of highly sensitive ELISAs it manufactures.

Key Points: 
  • Enzo is the provider of over 17,000 ELISA (enzyme-linked immunosorbent assay) and assay kits, including hundreds of highly sensitive ELISAs it manufactures.
  • The advanced design and technology of Enzos compact microplate reader makes it possible to deliver precise and accurate results.
  • Together with Enzos proprietary software, the device is an option for a wide variety of applications based on the miniaturization of Enzos assays.
  • With support from an instrument manufacturing company, the Enzo portable reader enables lab work to be executed outside of traditional research facilities (that rely on shared instrumentation).